# Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients

> **NCT02170025** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 21 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Riociguat (Adempas, BAY63-2521)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02170025
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09-30
- **Primary completion:** 2017-01-17
- **Final completion:** 2017-09-22
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Study was terminated after completion of Part 1, because Part 2 was no longer appropriate.
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02170025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02170025, "Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02170025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*